復星醫藥(600196.SH):Gland Pharma就股份在印度上市申請原則性批准
格隆匯7月12日丨復星醫藥(600196.SH)公佈,2020年5月8日,中國證券監督管理委員會國際合作部出具《關於上海復星醫藥(集團)股份有限公司分拆所屬企業境外上市有關事宜的函》,對本次分拆Gland Pharma境外上市事宜無異議。
公司獲通知,Gland Pharma已於2020年7月10日就建議首次公開發售其股份(即每股面值為1.00盧比的Gland Pharma股份,向Securities and Exchange Boardof India(即印度證券交易委員會,以下簡稱“SEBI”)、印度國家證券交易所及孟買證券交易所遞交非正式招股書草稿;並將就其股份在印度證交所及孟買證交所上市申請原則性批准。
預計本次分拆Gland Pharma境外上市將涉及Gland Pharma以首次公開發售的方式發行募資總額不超過1,250,000萬盧比的新股份,以及由Gland Pharma現有股東售出不超過34,863,635股的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.